Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Yann Echelard sold 10,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director now directly owns 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

TG Therapeutics Stock Up 0.5%

Shares of TGTX traded up $0.17 during mid-day trading on Thursday, reaching $35.17. 1,770,692 shares of the stock traded hands, compared to its average volume of 2,962,859. The stock has a fifty day simple moving average of $37.21 and a 200 day simple moving average of $34.81. TG Therapeutics, Inc. has a 12-month low of $16.65 and a 12-month high of $46.48. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. The firm has a market cap of $5.58 billion, a price-to-earnings ratio of 146.54 and a beta of 1.94.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same period last year, the firm earned ($0.07) EPS. The business's quarterly revenue was up 90.4% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of the business. Empowered Funds LLC grew its stake in TG Therapeutics by 6.1% during the 4th quarter. Empowered Funds LLC now owns 49,267 shares of the biopharmaceutical company's stock valued at $1,483,000 after purchasing an additional 2,836 shares in the last quarter. Van ECK Associates Corp purchased a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $4,219,000. New York State Teachers Retirement System grew its position in shares of TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock worth $1,317,000 after buying an additional 837 shares in the last quarter. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Finally, Valeo Financial Advisors LLC raised its holdings in TG Therapeutics by 32.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 13,532 shares of the biopharmaceutical company's stock valued at $407,000 after acquiring an additional 3,309 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TGTX has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.